This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_EPENDYDOMA_EXALLC for full statistics.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
60 |
4. Check minimum number of eventsNone |
60 |
5. Include endpointsNone |
60 |
6. Filter based on genotype QC (FinnGen only) |
60 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Ependymoma
based on the number of shared cases.
Similar with more cases:
- Ependymoma, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of eye, brain and central nervous system
- Malignant neoplasm of eye, brain and central nervous system, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm
- Any event in cancer register
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 60 | 36 | 24 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 46.43 | 43.60 | 50.68 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 54
- Matched controls
- 539
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
9391/3-C72.0
ICD-O-3
Ependymoma, NOS, of spinal cord
+∞
32.6
28
*
ABB00
NOMESCO Finland
Excision of lesion of spinal canal
+∞
16.5
15
*
ABB10
NOMESCO Finland
Resection of lesion of spinal canal
+∞
16.5
15
*
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
110.8
15.5
16
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
18.1
14.4
23
21
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
+∞
14.2
13
*
C71.74
ICD-10 Finland
Malignant tumor of the brainstem ependyoma
+∞
11.9
11
*
C72.09
ICD-10 Finland
Malignant tumor of the spinal cord other histology
+∞
11.9
11
*
C72.00
ICD-10 Finland
Malignant tumor of the spinal cord without histology
+∞
10.8
10
*
C72.01
ICD-10 Finland
Malignant tumor of the spinal cord grade II glioma
+∞
10.8
10
*
H02AB02
ATC
dexamethasone; systemic
12.0
10.6
20
25
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
+∞
9.7
9
*
C71.51
ICD-10 Finland
Malignant tumor of cerebral ventricle ependymoma
+∞
9.7
9
*
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
60.1
9.0
10
*
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
105.9
8.7
9
*
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
+∞
8.5
8
*
D43.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Spinal cord
+∞
8.5
8
*
9391/3-C71.7
ICD-O-3
Ependymoma, NOS, of brain stem
+∞
8.5
8
*
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
7.7
8.4
21
41
TAB00
NOMESCO Finland
Lumbar puncture
27.0
8.4
11
5
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
52.9
8.0
9
*
M03BX01
ATC
baclofen; systemic
92.2
7.6
8
*
D33.43
ICD-10 Finland
Spinal cord
+∞
7.5
7
*
D33.41
ICD-10 Finland
Myxopapillary epndymoma of the spinal cord (grade I)
+∞
6.4
6
*
9391/3-C71.5
ICD-O-3
Ependymoma, NOS, of ventricle, NOS
+∞
6.4
6
*
YX8BD
NOMESCO Finland
Stereotactic extensive CT examination for dose design of radiotherapy
+∞
6.4
6
*
G91.1
ICD-10 Finland
Obstructive hydrocephalus
+∞
6.4
6
*
D33.4
ICD-10 Finland
Benign neoplasm: Spinal cord
+∞
6.4
6
*
D33.40
ICD-10 Finland
Benign glioma of the spinal cord (grade I)
+∞
6.4
6
*
ZX050
NOMESCO Finland
Stereotactic radiotherapy
+∞
6.4
6
*
130
Kela drug reimbursment
Malignant tumour
9.9
6.2
12
15
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
24
45
8.22
13.61
6.2
7.2
0.51
1.51
mmol/l
1.15
15
35
43
217
4.46
6.76
3.5
4.2
—
—
—
0
0
16
42
4.83
6.00
8.2
14.7
23.88
24.88
mmol/l
0.71
16
42
26
114
3.26
4.63
3.1
2.6
—
—
—
0
0
5
6
8.94
2.80
1.8
5.0
6.00
13.33
%
—
5
6
5
6
8.94
2.80
1.6
1.7
—
—
—
0
0
5
6
8.94
2.80
1.8
5.2
27.40
27.83
%
—
5
6
5
7
7.65
2.60
1.8
4.6
—
—
—
0
0
5
7
7.65
2.60
1.4
1.3
—
—
—
0
0
15
68
2.61
2.35
5.8
3.2
29.87
30.10
s
0.07
15
68
6
13
5.00
2.33
4.7
5.6
16.33
21.28
nmol/l
—
6
13
26
375
0.46
2.24
4.0
3.3
—
—
—
0
0
28
173
2.16
2.18
3.4
3.5
—
—
—
0
0
36
249
2.11
2.06
10.0
7.4
8.83
10.29
umol/l
1.00
36
234
5
11
4.85
1.98
1.6
1.2
—
—
—
0
0
5
11
4.85
1.98
1.6
1.2
—
—
—
0
0
13
66
2.24
1.58
1.8
1.8
—
—
—
0
0
6
23
2.78
1.40
10.8
5.0
105.67
100.83
%
—
6
23
5
17
3.11
1.38
1.6
1.4
—
—
—
0
0
8
37
2.34
1.27
1.5
1.4
—
—
—
0
0
5
19
2.77
1.24
12.8
6.1
2.62
3.17
g/l
—
5
19
8
39
2.21
1.20
2.0
4.3
—
—
—
0
0
11
59
2.06
1.16
2.0
2.8
220.09
326.15
nmol/l
1.68
11
54
9
46
2.12
1.10
2.0
1.7
—
—
—
0
0
13
77
1.88
1.05
3.3
3.2
0.80
3.86
e6/l
—
5
42
55
499
2.22
1.01
18.9
13.3
26.52
18.45
mg/l
0.86
50
373
0
32
0.00
0.98
0.0
1.5
—
—
—
0
0
13
80
1.80
0.94
3.3
3.1
0.40
1.02
e6/l
—
5
45
8
42
2.04
0.93
2.1
1.6
—
—
—
0
0
8
47
1.81
0.84
8.4
13.2
1.52
1.77
mmol/l
—
8
37
22
164
1.54
0.78
4.0
3.5
2.36
2.36
mmol/l
0.12
22
146
7
120
0.53
0.78
1.7
1.6
—
—
—
0
0
25
193
1.51
0.75
2.1
2.9
80.12
79.37
nmol/l
0.03
25
173
8
51
1.65
0.64
3.6
10.0
—
—
—
0
0
5
89
0.52
0.61
1.2
1.5
—
—
—
0
0
0
20
0.00
0.61
0.0
1.7
—
—
—
0
0
0
20
0.00
0.61
0.0
1.4
—
—
—
0
0
0
19
0.00
0.61
0.0
1.5
—
—
—
0
0
0
19
0.00
0.61
0.0
1.5
—
—
—
0
0
0
19
0.00
0.61
0.0
1.5
—
—
—
0
0
0
23
0.00
0.59
0.0
1.1
—
—
—
0
0
20
155
1.44
0.57
2.8
4.1
15.30
42.95
ng/l
—
10
101
10
67
1.59
0.54
1.7
2.9
24.49
23.82
%
—
10
59
21
257
0.72
0.52
6.3
4.0
0.00
0.00
estimate
—
7
42
21
253
0.74
0.46
7.0
5.5
0.00
0.00
estimate
—
8
46
0
15
0.00
0.42
0.0
1.3
—
242.00
—
0
5
0
16
0.00
0.41
0.0
1.8
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
15
188
0.73
0.41
6.7
4.1
—
—
—
0
0
6
43
1.44
0.36
1.8
5.5
321.67
247.47
u/l
—
6
43
20
166
1.31
0.36
2.1
1.8
92.40
102.61
pmol/l
—
10
84
22
254
0.79
0.32
6.1
4.0
0.00
0.00
estimate
—
8
46
42
387
1.28
0.32
4.9
4.2
14.54
14.66
pmol/l
0.11
42
352
10
78
1.34
0.26
5.1
2.6
2.47
2.46
mmol/l
—
10
67
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
6
48
1.28
0.21
2.2
2.7
23.83
41.12
u/l
—
6
41
0
13
0.00
0.21
0.0
1.2
—
0.78
—
0
5
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
15
130
1.21
0.18
6.5
4.5
0.00
0.00
estimate
—
8
45
13
112
1.21
0.16
3.7
5.3
0.75
2.18
ug/l
5.71
13
98
7
87
0.78
0.16
2.0
1.9
451.86
477.00
pmol/l
—
7
74
6
58
1.04
0.08
1.8
2.0
—
—
—
0
0
44
431
1.08
0.03
18.5
11.7
91.22
86.52
ml/min/173m2
0.86
37
344
47
471
0.99
0.00
27.3
14.5
40.12
39.60
%
0.26
35
372
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
6
67
0.88
0.00
3.5
2.8
0.67
0.86
ug/l
—
6
44
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
292.25
—
0
8
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
0.67
—
0
6
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
5.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
3.8
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
5
0.00
0.00
0.0
1.0
—
119.20
—
0
5
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
6
67
0.88
0.00
1.8
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_EPENDYDOMA – Ependymoma
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).